• How to develop lyophilization protocols that preserve mRNA and LNP structural integrity to support long-term stability at 2–18°C and reduce cold chain dependency
• Mitigating particle size shifts and activity loss during lyophilization to maintain formulation quality and simplify product release decisions
• Characterizing and controlling LNP stability factors, such as particle size and encapsulation efficiency, to preserve potency throughout storage and transport

NOVEL MRNA MODALITY